Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Gynecologic 1

Conditions

Carcinoma, Non-Small-Cell Lung 27Breast Neoplasms 23Ovarian Neoplasms 19Triple Negative Breast Neoplasms 17Endometrial Neoplasms 16Lung Neoplasms 15Parkinson Disease 4, Autosomal Dominant Lewy Body 12Fallopian Tube Neoplasms 11Squamous Cell Carcinoma of Head and Neck 9Neoplasm Metastasis 9Neoplasms 6Esophageal Neoplasms 6Adenocarcinoma Of Esophagus 6Stomach Neoplasms 4Melanoma 4Esophageal Squamous Cell Carcinoma 4Cholangiocarcinoma 4Uterine Cervical Neoplasms 3Colorectal Neoplasms 3Carcinoma 3Uterine Neoplasms 2Urinary Bladder Neoplasms 2Peritoneal Neoplasms 2Pathologic Complete Response 2Head and Neck Neoplasms 2Carcinoma, Transitional Cell 2Carcinoma, Ovarian Epithelial 2Brenner Tumor 2Anatomic Stage I Breast Cancer AJCC v8 2Advanced Solid Tumour 2

Interventions

temsirolimus 1ixabepilone 1Taxes 1Sirolimus 1Paclitaxel 1Immunoglobulin G 1Epothilones 1Disulfides 1Carboplatin 1Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Endometrial Adenocarcinoma × Paclitaxel × 30 days × Clear all
NCT00977574 2026-05-29

Paclitaxel, Carboplatin, and Bevacizumab or Paclitaxel, Carboplatin, and Temsirolimus or Ixabepilone, Carboplatin, and Bevacizumab in Treating Patients With Stage III, Stage IV, or Recurrent Endometrial Cancer

National Cancer Institute (NCI)

Phase 2 Active not recruiting
349 enrolled 11 charts
GynecologicSarcoma

Endometrial Adenocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡